{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Descriptive statistics will be used to summarize the expression of biomarkers and the concentrations of plasma erlotinib hydrochloride. The Wilcoxon rank sum test will be used to compare the expressions of biomarkers and concentrations of plasma erlotinib hydrochloride between patients with and without response.","groups":[{"description":"Patients receive erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nErlotinib Hydrochloride: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies","id":"OG000","title":"Treatment (Erlotinib Hydrochloride)"}],"populationDescription":"Samples and data required for the above outcome measure were not done, therefore we cannot report any outcomes for the above outcome measure.","reportingStatus":"POSTED","timeFrame":"Up to 30 days","title":"Biomarker Expressions","type":"SECONDARY"}